Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevu
Certain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made a draft recommendation that the NHS should fund Roche’s cocktail i
NICE has launched a new resource to help identify and support new health technologies for the UK health system to adopt, to hasten patients’ access to the cutting-edge medical devices, diag
The Institute for Cancer Research has called for action to improve access to innovative cancer treatments after a new survey found that many UK patients are being denied drugs and see the p
NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.
People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig if they fail other therapies, according to the country’s cost-effectiveness